Amendment: SEC Form SCHEDULE 13D/A filed by Core Scientific Inc.

Item 3 of the Schedule 13D is hereby amended and restated as follows: The aggregate purchase price of the 2,630,950 shares of Common Stock directly held by the Strategic Fund reported herein was $36,028,987.73. The aggregate purchase price of the 13,283,098 shares of Common Stock, 20,340 options to purchase Common Stock and 313,646 warrants directly held by the Global Fund reported herein was $146,749,421.80. The aggregate purchase price of the 454,985 shares of Common Stock directly held by the Accounts reported herein was $7,180,487.49. Further, the securities of the Issuer directly held by the Funds and Accounts were purchased with the working capital of the Funds and Accounts (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business).

Each of the Reporting Persons may be deemed to beneficially own 18,716,679 shares of Common Stock of the Issuer, which includes 313,646 shares of Common Stock issuable upon exercise of warrants and options to purchase 2,034,000 shares of Common Stock. Such amount of beneficial ownership represents approximately 5.9% of the shares of Common Stock outstanding, based on 315,332,655 shares of Common Stock outstanding as of February 26, 2026, based on information disclosed in the Issuer's Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 2, 2026, plus 313,646 shares of Common Stock issuable upon the exercise of warrants held by the Funds. The Funds and Accounts have delegated to TSC sole voting and investment power over the securities held by the Funds and Accounts pursuant to their respective Investment Management Agreements with TSC. As a result, each of TSC, TSC GP, as the general partner of TSC, and Mr. Toussi, as Chief Investment Officer of TSC and Managing Member of TSC GP, may be deemed to exercise voting and investment power over the securities of the Issuer directly held by the Funds and Accounts. The Funds and Accounts specifically disclaim beneficial ownership of the securities of the Issuer directly held by them by virtue of their inability to vote or dispose of such securities as a result of their respective Investment Management Agreements with TSC. The information in Item 3 regarding the securities held by the Funds and Accounts is incorporated herein by reference. The options to purchase Common Stock consist of options to purchase 1,500,000 shares of Common Stock held by the Global Fund with an exercise price of $18 that expire on March 20, 2026, and options to purchase 534,000 shares of Common Stock held by the Global Fund with an exercise price of $20 that expire on April 17, 2026. The Global Fund has also purchased options to sell 2,431,000 shares of Common Stock with an exercise price of $17 that expire on April 17, 2026. The Global Fund also has sold options to purchase 1,500,000 shares of Common Stock with an exercise price $23 that expire on March 20, 2026, and options to sell 2,431,000 shares of Common Stock with an exercise price $14 that expire on April 17, 2026. In addition, the Strategic Fund has sold options to purchase 485,100 shares of Common Stock with an exercise price of $20 that expire on April 17, 2026, and options to sell 485,100 shares of Common Stock with an exercise price of $14 that expire on April 17, 2026. The Strategic Fund has also purchased options to sell 485,100 shares of Common Stock with an exercise price of $17 that expire on April 17, 2026. Further, the Accounts have sold options to purchase 83,900 shares of Common Stock with an exercise price of $20 that expire on April 17, 2026, and options to sell 83,900 shares of Common Stock with an exercise price of $14 that expire on April 17, 2026. The Accounts have also purchased options to sell 83,900 shares of Common Stock with an exercise price of $17 that expire on April 17, 2026.

Items 7 through 10 of each of the cover pages of this Schedule 13D are incorporated herein by reference. The information in Item 3 regarding the securities held by the Funds and Accounts is incorporated herein by reference.

Transactions by the Reporting Persons (on behalf of the Funds and Accounts) effected since the previous amendment to Schedule 13D was filed with the SEC on February 19, 2026, are set forth in Exhibit 99.1 and such information is incorporated herein by reference.

The disclosure regarding the relationship between the Reporting Persons in Item 2(c) of this Schedule 13D is incorporated herein by reference. All securities reported in this Schedule 13D are directly held by the Funds and Accounts, each of which are investment management clients of TSC. The limited partners of (or investors in) each of the Funds and Accounts have the right to participate in the receipt of dividends from, or proceeds from the sale of, the securities of the Issuer held for the accounts of their respective Funds or Accounts in accordance with their respective limited partnership interests (or investment percentages) in their respective Funds or Accounts.

Not applicable.

Item 6 of this Schedule 13D is supplemented and superseded, as the case may be, as follows: The information in Item 5 of this Schedule 13D is incorporated herein by reference.

99.1 Transactions Effected by the Reporting Persons (on Behalf of the Funds and Accounts) Following February 19, 2026.